Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses

Journal of Medical Virology

Volumn 89, Issue 6, 2017, Pages 1040-1047

  Elfiky, Abdo A ^a,b   Mahdy, Samah M ^a,c   Elshemey, Wael M ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b ABDUS SALAM INTERNATIONAL CENTRE FOR THEORETICAL PHYSICS   (Italy)

^c Ain Elsira Elfustat ^*  (Egypt)

Author keywords

docking; HCV; human coronavirus; nucleotide inhibitor; polymerase; QSAR

Indexed keywords

ANTIVIRUS AGENT; IDX 184; MERICITABINE; MK 0608; NONSTRUCTURAL PROTEIN 5B; RIBAVIRIN; SOFOSBUVIR; UNCLASSIFIED DRUG; DNA DIRECTED RNA POLYMERASE;

ARTICLE; BETACORONAVIRUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONAVIRIDAE; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; HYDROGEN BOND; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR DOCKING; NONHUMAN; POLYMERIZATION; PROTEIN SECONDARY STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; VIRUS MORPHOLOGY; VIRUS REPLICATION; VIRUS STRAIN; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG REPOSITIONING; ENZYMOLOGY; PRECLINICAL STUDY; SARS CORONAVIRUS;

ANTIVIRAL AGENTS; DNA-DIRECTED RNA POLYMERASES; DRUG EVALUATION, PRECLINICAL; DRUG REPOSITIONING; MOLECULAR DOCKING SIMULATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SARS VIRUS;

EID: 85013276209     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24736     Document Type: Article

References (46)

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. 2012. Isolation of a novel Coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 367:1814–1820.
2. Zumla AC, Azhar JF, Hui EI, Yuen DS, KY. 2016. Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov. 15:327–347.
3. van den Brand JMA, Smits SL, Haagmans BL. 2015. Pathogenesis of Middle East respiratory syndrome coronavirus. J Pathol. 235:175–184.
4. Sharif-Yakan A, Kanj SS. 2014. Emergence of MERS-CoV in the Middle East: origins, transmission, treatment, and perspectives. PLoS Pathog. 10:e1004457.
5. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, Luo SW, Li PH, Zhang LJ, Guan YJ, Butt KM, Wong KL, Chan KW, Lim W, Shortridge KF, Yuen KY, Peiris JS, Poon LL. 2003. Isolation and characterization of viruses related to the SARS Coronavirus from animals in southern China. Science. 302:276–278.
6. WHO, 2016. Middle East respiratory syndrome coronavirus (MERS-CoV) WHO.
7. Huynh J, Li S, Yount B, Smith A, Sturges L, Olsen JC, Nagel J, Johnson JB, Agnihothram S, Gates JE. 2012. Evidence supporting a zoonotic origin of human coronavirus strain NL63. J Virol. 86:12816–12825.
8. Vijgen L, Keyaerts E, Moes E, Thoelen I, Wollants E, Lemey P, Vandamme AM, Van Ranst M. 2005. Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J Virol. 79:1595–1604.
9. Corman VM, Baldwin HJ, Tateno AF, Zerbinati RM, Annan A, Owusu M, Nkrumah EE, Maganga GD, Oppong S, Adu-Sarkodie Y. 2015. Evidence for an ancestral association of human coronavirus 229E with bats. J Virol. 89:01755–01715.
10. Han HJ, Yu H, Yu XJ. 2016. Evidence for zoonotic origins of Middle East respiratory syndrome coronavirus. J Gen Virol. 97:274–280.
11. Sheahan T, Rockx B, Donaldson E, Sims A, Pickles R, Corti D, Baric R. 2008. Mechanisms of zoonotic severe acute respiratory syndrome Coronavirus host range expansion in human airway epithelium. J Virol. 82:2274–2285.
12. Belouzard S, Millet JK, Licitra BN, Whittaker GR. 2012. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 4:1011–1033.
13. Fouchier RA, Hartwig NG, Bestebroer TM, Niemeyer B, de Jong JC, Simon JH, Osterhaus AD. 2004. A previously undescribed coronavirus associated with respiratory disease in humans. Proc Natl Acad Sci USA. 101:6212–6216.
14. Coleman CM, Frieman MB. 2014. Coronaviruses: important emerging human pathogens. J Virol. 88:5209–5212.
15. Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM, Madani TA. 2014. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med. 370:2499–2505.
16. Reusken CB, Haagmans BL, Müller MA, Gutierrez C, Godeke GJ, Meyer B, Muth D, Raj VS, Smits-De Vries L, Corman VM, Drexler JF, Smits SL, El Tahir YE, De Sousa R, van Beek J, Nowotny N, van Maanen K, Hidalgo-Hermoso E, Bosch BJ, Rottier P, Osterhaus A, Gortázar-Schmidt C, Drosten C, Koopmans MP. 2013. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels a comparative serological study. Lancet Infect Dis. 13:859–866.
17. Hilgenfeld R, Peiris M. 2013. From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Antiviral Res. 100:286–295.
18. Stadler K, Masignani V, Eickmann M, Becker S, Abrignani S, Klenk HD, Rappuoli R. 2003. SARS-beginning to understand a new virus. Nat Rev Microbiol. 1:209–218.
19. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. 2015. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev. 28:465–522.
20. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. 2003. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 426:450–454.
21. Yeager CL, Ashmun RA, Williams RK, Cardellichio CB, Shapiro LH, Look AT, Holmes KV. 1992. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature. 357:420–422.
22. Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, Thiel V, Drosten C, Rottier PJ, Osterhaus AD, Bosch BJ, Haagmans BL. 2013. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 495:251–254.
23. Huang X, Dong W, Milewska A, Golda A, Qi Y, Zhu QK, Marasco WA, Baric RS, Sims AC, Pyrc K, Li W, Sui J. 2015. Human Coronavirus HKU1 spike protein uses O-Acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-Esterase protein as a receptor-Destroying enzyme. J Virol. 89:7202–7213.
24. Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, Pohlmann S. 2005. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci USA. 102:7988–7993.
25. van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, Osterhaus AD, Haagmans BL, Gorbalenya AE, Snijder EJ, Fouchier RA. 2012. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio. 3:e00473-12.
26. Yang PL, Gao M, Lin K, Liu Q, Villareal VA. 2011. Anti-HCV drugs in the pipeline. Curr Opin Virol. 1:607–616.
27. Elfiky AA, Elshemey WM, Gawad WA, Desoky OS. 2013. Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes. Protein J. 32:75–80.
28. Asselah T. 2014. Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy. J Hepatol. 61:435–438.
29. Elfiky AA, Elshemey WM. 2016. IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study. Med Chem Res. 25:1005–1008.
30. Saleh NA. 2014. The QSAR and docking calculations of fullerene derivatives as HIV-1 protease inhibitors. Spectrochim Acta A Mol Biomol Spectrosc. 136PC:1523–1529.
31. Rodrigues JP, Bonvin AM. 2014. Integrative computational modeling of protein interactions. FEBS J. 281:1988–2003.
32. Elfiky AA, Elshemey WM, Wissam AG. 2015. 2′-Methylguanosine prodrug (IDX-184), phosphoramidate prodrug (Sofosbuvir), diisobutyryl prodrug (R7128) are better than their parent nucleotides and ribavirin in hepatitis C virus inhibition: a molecular modeling study. J Comput Theor Nanosci. 12:376–386.
33. Summers KL, Mahrok AK, Dryden MD, Stillman MJ. 2012. Structural properties of metal-free apometallothioneins. Biochem Biophys Res Commun. 425:485–492.
34. Squizzato S, Park YM, Buso N, Gur T, Cowley A, Li W, Uludag M, Pundir S, Cham JA, McWilliam H, Lopez R. 2015. The EBI Search engine: providing search and retrieval functionality for biological data from EMBL-EBI. Nucleic Acids Res. 43:W585–W588.
35. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Soding J, Thompson JD, Higgins DG. 2011. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol. 7:539.
36. Robert X, Gouet P. 2014. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 42:W320–W324.
37. Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. 2015. The I-TASSER Suite: protein structure and function prediction. Nat Methods. 12:7–8.
38. Colovos C, Yeates TO. 1993. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci. 2:1511–1519.
39. Pontius J, Richelle J, Wodak SJ. 1996. Deviations from standard atomic volumes as a quality measure for protein crystal structures. J Mol Biol. 264:121–136.
40. O'Farrell D, Trowbridge R, Rowlands D, Jäger J. 2003. Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation. J Mol Biol. 326:1025–1035.
41. Noolvi MN, Patel HM. 2013. A comparative QSAR analysis and molecular docking studies of quinazoline derivatives as tyrosine kinase (EGFR) inhibitors: a rational approach to anticancer drug design. J Saudi Chem Soc. 17:361–379.
42. Xu X, Liu Y, Weiss S, Arnold E, Sarafianos S G, Ding J. 2003. Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. Nucleic Acids Res. 31:7117–7130.
43. SchrödingerLLC.1.7.6, V., The PyMOL Molecular Graphics System, Version 1.7.6
44. Bellissent-Funel M-C, Hassanali A, Havenith M, Henchman R, Pohl P, Sterpone F, van der Spoel D, Xu Y, Garcia AE. 2016. Water determines the structure and dynamics of proteins. Chem Rev. 116:7673–7697.
45. Zhou XJ, Pietropaolo K, Chen J, Khan S, Sullivan-Bolyai J, Mayers D. 2011. Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects. Antimicrob Agents Chemother. 55:76–81.
46. Elfiky AA. 2016. Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials. J Med Virol. 88:2044–2051.